awmsg logo



epoetin alfa (Eprex®)


Reference No. 3138

Publication date:
13/07/2017


Appraisal information

epoetin alfa (Eprex®) 2000 IU/ml solution for injection
epoetin alfa (Eprex®) 4000 IU/ml solution for injection
epoetin alfa (Eprex®) 10000 IU/ml solution for injection
epoetin alfa (Eprex®) 40000 IU/ml solution for injection


Company: Janssen-Cilag Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 12/07/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, epoetin alfa (Eprex®) cannot be endorsed for use within NHS Wales for the treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (< 200 mU/mL).
Statement of Advice (SOA)
Download